Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I find it hard to believe that some people are still willing to defend Bignitz and his fellow scoundrels. By suggesting that it’s fine for them to have entered into such a toxic loan agreement with DGF, because surely they must have had the advice of their lawyer, is an insult to any shareholder that can read.
Notwithstanding the fact that ultimately the responsibility lies with the CEO, an agreement of such magnitude would have also involved input from the CFO, Chairman of the Board, and their lawyer.
With regards to the above I wrote a scathing email to the company’s lawyer. I wrote in part:
The Quarterly Report (10-q) was out after closing.
https://ih.advfn.com/stock-market/USOTC/owc-pharmaceutical-research-OWCP/stock-news/81138772/quarterly-report-10-q
The following is a good summary of why the company is in the mess that it's in.
Here is the answer to your specific question:
You do not have to agree with what I wrote. Of course, you are entitled to your opinion. What I wrote in that email is all factual and it hit a nerve. So much so that the company wanted me to sign an NDA before they would comment further on the specific issues that I raised. I refused to sign it because I did not want to be muzzled.
Furthermore I am hardly alone here with what I wrote. There are many posters that have had the same frustrating experience and that share the same view and opinion.
With all due respect, posters like I-Glow and Homebrew, and several others have been saying consistently from day one that the share selling scheme was concocted in 2014. The fact that it rose from the ashes to $3+ due to the pumping, and now it's returned back to ashes again should tell anyone all they need to know. The difference now is that all investors have to do is a minimum amount of due diligence to come to the same conclusion that the aforementioned posters came to years ago. The company exists only for the purpose of selling shares. Now that it seems they have reached the end of the road, they are desperately trying figure out ways of keeping the gravy train going before it runs out of steam.
For anyone to suggest that the past is "immaterial in forecasting the future of the company" does not make sense. Especially when it's clear how the company was concocted, and especially so when it's a documented fact that the company has nothing to show for it, except in the imagination of those that still believe in the crap that occasionally the company puts forth.
Finally, let me just say that I had very serious doubts and concerns about the company within just a few weeks after initially investing in the company. These doubts and concerns were brought to the attention of management and I was fed one lie after another. But each time I gave them the benefit of the doubt and dismissed posters like I-Glow. I know that hindsight is 20-20 but I shouldn't have been so stupid and naive. I sincerely regret my positive comments of the past and the possible role that I may have had in influencing other investors. For that I'm truly sorry, and hope that the bitter lesson learned will serve them well in their future investment decisions.
Good luck to all!
Here is my one post of the day so I apologize in advance if it’s lengthy.
With regards to the previous R/S below is an email that I sent to Mr. Kenneth Koch back in April of this year. Obviously in the interim nothing has changed except giving us more reason to be upset, and justification for the added adjectives hurled to the pigs and criminals at management and those who support them. Yes, those who support them, are complicit, and are turning a blind eye to the scam that is going on, all for the almighty dollar! Yes, that includes Koch, Rubin, Sims, V-Stock Transfer, and let us not forget, all the “research facilities” that are supposedly conducting the “science” and profiting from those shareholders that have been victimized by the fraud that has been and continues to be committed.
We have every right to be pissed off. Nobody likes to be robbed. Thieves can end up in jail for stealing a chocolate bar, meanwhile for these vultures it’s business as usual. Feel free to forward this to everybody in management and anybody else that you can think of. Here are their emails:
KRKoch@mintz.com
mordechai.bignitz@owcpharma.com
stanley.hirsch@owcpharma.com
Sigal.Russo@owcpharma.com
alon.sinai@owcpharma.com
yehuda.baruch@owcpharma.com
jeffrey@jeffreyfriedland.com
rrubin@parkavenuegroup.us
For the sake of transparency, I’m glad that I held most of my shares until yesterday’s Record Date. Today I sold all of my shares in one of my accounts, but I am still entitled to vote. Not sure if it will make any difference but I plan to vote NO just as I did the last time. You may ask why sell now? For me the reason is very simple. My shares are worth much more dead than alive! The capital loss will offset my income tax on other significant capital gains.
Having said all of the above, it is my sincere wish that there is a miracle rebound so that many of you can recoup some of your losses. Given my record with timing that could very well happen.
Here is an email that was sent to OWCP’s lawyer and then no doubt forwarded to management. It’s already been shared with some of you. Remember my one-post limit, so I won’t be able to reply.
Good luck!
Former Teva CEO Jeremy Levin talks to "Globes" about Israel's biotech potential, the opioid disaster and why he shuns investing in medical cannabis.
https://en.globes.co.il/en/article-from-tevas-ashes-israeli-biotech-can-grow-1001303213
An interesting perspective from someone that knows a thing or two about the biotech industry.
New 8-k out!
https://sec.report/Document/0001493152-19-015116/
Item 8.01 Other Events.
OWC Pharmaceutical Research Corp. (“OWC”) announced that, on September 25, 2019, One World Cannabis Ltd., a company organized and existing under the laws of Israel and a wholly-owned subsidiary of OWC received Top Line Results (TLR) of its single-dose, randomized, crossover study to compare the safety, tolerability and pharmacokinetics (PK) of OWC’s Medical Grade Cannabis - Orally Disintegrating Tablets (MGC-ODT) vs. buccal Sativex®, in healthy adult volunteers. The study was conducted at the Sourasky Medical Center in Tel Aviv. In this study, participants were administered randomly, either Sativex (5.4 mg THC, 5.0 mg CBD) or OWC-ODT (4.2 mg THC, 5 mg CBD), and then crossed over, with a minimum interval of two weeks. Plasma was collected in the 24 hours following drug administration, at pre-determined time points, and side effects were monitored. The concentrations of THC, CBD and 11-OH-THC were quantified, and their plasma PK determined.
The TLR show that both MGC-ODT and Sativex® administration had comparable mean times of peak concentration, half-life and elimination rates for each of the three analytes (THC, THC metabolite 11-hydroxy-THC and CBD). The results indicated dose-related comparability of both products in rate of absorption and bioavailability. The incidence of treatment related adverse events (AEs) were similar between the treatments.
The most common treatment related AEs were hunger (reported in 25% of subjects treated with MGC-ODT), thirst (reported in 18.75% and 6.25% of subjects treated with MGC-ODT and Sativex®, respectively), dizziness (reported in 18.75% and 18.75% of subjects treated with MGC-ODT and Sativex®, respectively), dysgeusia (reported in 12.5% and 25% of subjects treated with MGC-ODT and Sativex®, respectively). Administration of MGC-ODT was judged to be well tolerated and no unexpected safety signals were observed.
Top Line Results Conclusions: OWC- Orally Disintegrating Tablet is safe to use and appears to have similar PK and bioavailability as Sativex® . Therefore, OWC intends to apply to the Israel Ministry of Health to obtain necessary approvals to market its Medical Grade Cannabis - Orally Disintegrating Tablets in Israel.
You are a psoriasis expert. If I'm not mistaken you have your own product line on the market under the "Let it Glow" label...My apologies if this is not correct.
https://www.sephora.com/product/let-it-glow-supermud-set-P423483?country_switch=ca&skuId=1998228&om_mmc=disp-10344689-140194150-92493299
Because he's a bastard in a basket?
I only have 125,000 shares left and I regret not selling them a few weeks ago for a case of premium beer and taco chips...Damn!
I realize that is your opinion and you are right that the company does not have a "clue" on how to pump their stock. How odd but that is EXACTLY what I and many others here like about OWCP! But I must admit it's really boring that they just stick to the facts and they don't really embellish them as much as they could. If they lied then I guess they would meet your expectations.
Why in the world would OWCP management address a random "news article" from a whisperer website????
1. Because it's a good business practice to do so.
2. Not doing so could either derail or negatively impact the negotiations
3. If "rumors" were to lead to unusual market activity the SEC rules would require the company to issue a statement regarding the rumors, so why not pre-empt it.
4. They were probably advised, prudently I might add, to issue the 8-K by their lawyers.
There could be many other reasons as well why a statement was issued. To the relief of a few here, maybe it was also to tell us that they are not asleep, they are in fact fully awake, and working hard to further the fortunes of the company and its shareholders.
Would you feel more assurance if there was music from a piano playing in the background? Crickets chirping are annoying!
A news release for the sake of a news release just to appease shareholders is not only ridiculous, but counter-productive. Many of us are ok waiting for when there is real news.
This could be the big break we’ve been waiting for? Surely you are kidding, and if you are it's not very funny! A sicko perhaps may be waiting for this, but neither OWCP nor it's investors are hoping for a nuclear holocaust.
The 10-Q has to be filed today as per the SEC rules.
Far from it. That's what he was trying to be. How about getting back to the task at hand, and that is VDRM?
Agreed! It will be be so huge that it will eclipse not only any other trading day, it will also eclipse the solar eclipse.
"its ran" is grammatically incorrect.
From MICROCAP DAILY:
CLKA) $0.0114 (BREAKOUT!) SUPER-COLOSSAL SLEEPER!
http://www.microcapdaily.com/new-pick-is/
True, people don't buy or sell because of the emails. But they did elect a president because of them. LOL!
Good for you for reaching out to management for clarification. Without exception they have always replied to my emails. As for the clinicaltrials.gov study I never quite got a satisfactory answer, but from what I gather it was replaced and conducted in Israel instead. It was explained to me in detail that it is not at all unusual to encounter delays in these types of clinical trials, but as far as we know they are still on schedule.
Understandably management has to be very careful on how they reply. It can be a fine line between what is considered to be insider information and what is not. So if they come across as guarded and somewhat paranoid, that is the reason. I have no issue with what they cannot disclose.
But I will readily admit that they could have done, and could do, a much better job of setting the record straight on misinformation. Hopefully with the recent changes in management, they will do just that. This is my one post for the day. GLTA!
Thank you for pointing out that Dr. Yehuda Baruch is a genius. He is a great asset to OWCP and we are happy to know he will be leading its research for years to come. There is NO OTHER person that is more qualified.
Yes I read the latest 10-K Amendment in detail. Not sure if you have any specific questions but it is exactly the same as the original 10-K. The only difference between the two pertains to the "Evaluation of Disclosure Controls and Procedures" ITEM 9A on page 67. The wording in the first clause was incorrect in the initial 10-K and it was amended with:
Thanks for the info, even if it is VERY old news! The second link tells me that his credentials are impeccable and a huge asset to OWCP. As for the first link what can I say...never mind I was going to say maybe he could run for president, but that would be a cheap shot at you know who. GLTA!!!!
Less than 12 hours ago you said "stay out for 3 months", now it's 4 months. Has anything changed in the meantime, are you confused, or was that a typo?
There is an update on the lawsuit. Preliminary conference order scheduled for December 12, 2017.
https://iapps.courts.state.ny.us/nyscef/DocumentList?docketId=gMeR_PLUS_Kz6QjVcnZmVohq9XA==&display=all&courtType=New%20York%20County%20Supreme%20Court
The lawsuit is progressing as expected. My guess is that the law firm will be eager to settle without going to trial. I doubt that they will want to take a chance of having a malpractice judgement against them.
https://iapps.courts.state.ny.us/nyscef/DocumentList?docketId=gMeR_PLUS_Kz6QjVcnZmVohq9XA==&display=all&courtType=New%20York%20County%20Supreme%20Court
Yes I agree that if OWCP's product comes out, internet forums will not affect the stock price. The product sales will determine everything. That is true!
You have to be kidding, of course, when you state that its success depends on press releases. If that were indeed the case we would be doing a happy dance with every 8-K and every press release and laughing all the way to the bank. But you can mark my word: Our day will come soon enough, and many of you will be left looking in the rear-view mirror!
Your statement is incorrect, all of the patent applications have not been rejected.
GREAT NEWS: EUROPEAN PATENT FILED
https://finance.yahoo.com/news/owc-pharmaceutical-research-takes-further-110000839.html
One World Cannabis Ltd. (OWC), has filed a patent application with the European Union Patent and Trademark Office for its active cannabinoid-based psoriasis topical cream. (The patent application number is EP 17178303.8)
That is quite the statement you made:
The reply you received is consistent with the one that I got:
"Just wait until we announce the new CFO , on or before July 1st.
You will review his resume , compare it to Mr. De Saban's and than we will talk".
Gary I'm not sure where you got the impression that the company intends to proceed on MM trials first, before the Psoriasis Cream. The Psoriasis Cream safety study is definitely on track. The MM clinical study may begin in the 3rd quarter of 2017 as well.
With regards to the Psoriasis Cream, the last 10-Q stated the following:
Pursuant to the Research Agreement, the Fund shall perform a Phase I, double blind, randomized, placebo-controlled, maximal dose study (the "Study") to determine the safety, tolerability of topical cream containing MGC ("Medical Grade Cannabis" or the "Study Drug") in healthy volunteers, employing the services of Dr. Aviv Barzilay, Director of the Department of Dermatology- Chaim Sheba Medical Center, Tel Hashomer, Israel, to lead the Study (the "Investigator"). The Study shall be conducted in compliance with the following, as defined in the Research Agreement: (1) the Protocol; (2) the Ministry Guidelines; (3) the instructions and terms specified in the Helsinki Committee's approval; (4) the ICH-GCP; (5) the Helsinki Declarations; (6) the applicable laws, rules and regulations regulating such studies which are applicable in Israel (the "Applicable Laws"); and (7) written instructions and prescriptions issued by the OWC and governing the administration of the Study Drug.
On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Company determined to extend the size and scope of the Study for the purpose, among other things, of checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, we expect to complete the Study during the 2nd or 3rd quarters of 2017.
Below is a summary of the collaboration agreement with Sheba Academic Medical Centre and its Status for both Multiple Myeloma and Psoriasis:
Multiple Myeloma:
? Entered into a research agreement for in vitro studies
? Negotiating terms of a research agreement for in vivo studies
? Completed one in vitro study
? Proceeding with further pre-clinical in vitro studies (safety and toxicity, pharmacokinetic, and pharmacodynamic)
? Expect to submit a clinical trial protocol to the Israeli Institutional Review Board and receive its approval to commence a clinical study
? Intend to commence a clinical study in the third quarter of 2017
? Drafted a clinical trial protocol synopsis, which we believe will assist us in preparing an application for orphan status designation
Psoriasis:
? Entered into a Research Collaboration and License Agreement but have not commenced any studies to date
? Received an IRB approval for a Phase I, double blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers. The study began in April 2017
The company has been able to keep the amounts spent on R&D low because of the numerous collaboration agreements that they have in place. Their principal collaborator happens to be Sheba Academic Medical Centre. This is spelled out many times in the 10-K, 10-Q and other reports filed. They are of course relinquishing some of the IP rights to Sheba but this is well worth it. FYI, collaborations and affiliations with research facilities is a common practice with many of the Pharmas starting out. It's a smart way of keeping costs down. Give management credit!
The salaries are very low and they are indeed spelled out. One way of motivating and compensating the "employees" is by offering incentives to the OWCP doctors and research team. This is much better than giving each of them fat salaries. Makes good sense to me!
What is so funny about having almost two million dollars in the bank?
That is funny. Incredible but some people actually believe that we should urge management to renegotiate their collaboration agreements with Sheba to see if they could pay more. You just cannot teach common sense.
Yes I see that I misunderstood your post. But I would not want for the company to rest on its laurels. For the many investors that got in this year, the gains have been modest at best. But there are too many that are seeing red...literally and figuratively. For their sake, and others too, I hope the stock goes up 22,000% from their entry level.
There is a reason for the small amount of money spent on R&D. Some, like you, have expressed a concern but it should not be. Read the 10-Q and the 10-K and for that matter other reports that have been filed. You keep coming across the term "Collaboration Agreements". With regards to R&D OWCP's principal Collaborator is Sheba Academic Medical Center. If it were not for relinquishing some of the intellectual property rights to Sheba, the fees paid to them would be much much higher. I think this is a smart way of keeping costs down. Give management credit!! Others have pointed out here that this type of collaboration with hospitals and universities is a very common practice.
The following is a quote from the most recent 10-Q:
That is a very impressive return. A 22,000% gain over 8 months at today's share price of $0.68 means your average buy price is $0.0031. It's even more impressive to those of us that know the 52 week range has been $0.0030 to $3.23. So at what point will your greed give way to reality. You have already passed on over 100,000%. Just curious. Thanks!!
They are speaking tomorrow at 12:25 pm. (6:25 am EDT). They are the 2nd. last presenters at the conference. That is actually very good in that their presentation will be fresh in the minds of those that are present.
Here is the schedule:
Tuesday, 25th April 2017 - Monaco
6:30pm – 8:00pm Welcome Reception at the Maison du Caviar featuring Cascina Ballarin Premium Wines
Wednesday, 26th April 2017 - Monaco
9:00 am – 9:30 am: Coffee and pastries served
9:15 am – 9:30 am: Opening Remarks by Andreea Porcelli
9:30 am – 9:55 am: Foresight Autonomous Holdings Ltd. (TASE: FRST)
9:55 am – 10:20 am: KinerjaPay Corp. (OTCMKTS: KPAY)
10:20 am – 10:45 am: Jaguar Animal Health (NASDAQ:JAGX)
10:45 am – 11:10 am: BioSig Technologies (OTCQB: BSGM)
11:10 am – 11:35 am: Apollo Enterprise Solutions (AES:BH; OAL:GR)
11:35 pm – 12:00 pm: Nano Dimension (NASDAQ/TASE: NNDM)
12:00 pm – 12:25 pm: Prince of Venice
12:25 pm – 12:50 pm: OWC Pharmaceutical Research Corp.
12:50 pm – 1:15 pm: TechCare Ltd. (OTCQB: TECR)
1:15 pm – 2:30 pm: Seated buffet lunch
2:30 pm – 5:30 pm: One-on-One Meetings between delegates and company representative in 30-minute increments at the Wine Palace at the Yacht Club
5:30 pm – 7:00 pm: Italian Barolo Wine Tasting Reception at the Wine Palace at the Yacht Club featuring Cascina Ballarin Premium Wines
8:00pm – 10:30pm: Three-Course Gourmet Gala Dinner at Maison du Caviar (By invitation only)
Your question: "Will the cannabinoid creme work on Psoriasis?"
Answer: MOST DEFINITELY YES!!!!!!!